Literature DB >> 7632629

A quantitative sleep-EEG study on the effects of benzodiazepine and zopiclone in schizophrenic patients.

N Kajimura1, M Kato, T Okuma, M Sekimoto, T Watanabe, K Takahashi.   

Abstract

Polysomnographic examinations (PSG) were performed on 6 male schizophrenic outpatients who were being treated with benzodiazepine (BZD) hypnotics in combination with neuroleptics and 6 healthy male volunteers. In schizophrenic subjects, zopiclone (ZPC), 15 mg/day, was substituted for the BZD hypnotics, and PSGs were recorded again during ZPC therapy. All-night sleep stage scoring was carried out by visual analysis, and computerized period-amplitude analysis of sleep EEG was also performed. The schizophrenics showed marked reduction in the amount of slow-wave sleep (SWS) and in the number of delta half-waves during all-night sleep, especially those with higher amplitude, as compared to the normals. The number of delta half-waves in the patients was markedly reduced during the first sleep cycle. The average amplitude of delta half-waves during all-night sleep in the schizophrenics was significantly lower than that in the normals. The half-wave count of total delta waves in the schizophrenics was higher during treatment with ZPC than with BZDs, although no significant differences were observed in the amount of SWS between the two treatments. Soundness of sleep in the subjective sleep assessment was better evaluated during treatment with ZPC than BZDs. These results suggest that reduction of SWS in schizophrenia may be attributable mainly to the decrease in the number of delta waves with higher amplitude and that ZPC may induce deeper sleep in schizophrenics than BZDs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7632629     DOI: 10.1016/0920-9964(94)00054-c

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner.

Authors:  Ramadhan Oruch; Erlend Hodneland; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2009-04-30

2.  The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial.

Authors:  Cenk Tek; Laura B Palmese; Andrew D Krystal; Vinod H Srihari; Pamela C DeGeorge; Erin L Reutenauer; Sinan Guloksuz
Journal:  Schizophr Res       Date:  2014-10-29       Impact factor: 4.939

Review 3.  Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia.

Authors:  S Noble; H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

Review 4.  GABA(B) receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications.

Authors:  Joshua Kantrowitz; Leslie Citrome; Daniel Javitt
Journal:  CNS Drugs       Date:  2009-08       Impact factor: 5.749

5.  Insomnia comorbid to severe psychiatric illness.

Authors:  Adriane M Soehner; Katherine A Kaplan; Allison G Harvey
Journal:  Sleep Med Clin       Date:  2013-09

Review 6.  Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia.

Authors:  Lauren Stummer; Marija Markovic; Megan E Maroney
Journal:  Medicines (Basel)       Date:  2018-08-11

Review 7.  Sleep Abnormalities in Schizophrenia: State of the Art and Next Steps.

Authors:  Fabio Ferrarelli
Journal:  Am J Psychiatry       Date:  2021-03-17       Impact factor: 18.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.